Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Race Oncology Ltd. ( (AU:RAC) ) has issued an announcement.
Racura Oncology Limited, an ASX-listed Phase 3-stage clinical biopharmaceutical company, develops small-molecule cancer therapies led by (E,E)-bisantrene, which silences the MYC oncogene through G4-DNA and RNA binding and benefits from long-duration patent protection. The company’s pipeline is centred on its proprietary RC220 formulation, with late-stage development in acute myeloid leukaemia, early-stage trials in EGFR-mutant non-small cell lung cancer, and combination strategies with doxorubicin to improve both efficacy and cardiac safety, underpinned by extensive academic collaborations and an active search for strategic partners.
Racura has released the presentation for its inaugural Research & Development Symposium in Sydney, an investor-focused event designed to deepen understanding of its science and clinical pipeline. The symposium materials, enhanced with embedded QR-linked multimedia and a forthcoming video recording, aim to showcase the company’s technological positioning and development strategy to current and prospective investors, potentially strengthening market confidence and support for its advancing oncology programs.
The most recent analyst rating on (AU:RAC) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Limited is an ASX-listed, Phase 3-stage clinical biopharmaceutical company focused on oncology, with a mission to silence cancer. Its lead asset is (E,E)-bisantrene, a small-molecule anticancer agent that targets G4-DNA and RNA to silence the MYC oncogene, supported by new composition-of-matter intellectual property providing 20 years of patent protection.
The company is advancing its proprietary formulation RC220 across multiple indications, including a Phase 3 program in acute myeloid leukaemia, Phase 1a/b trials in EGFR-mutant non-small cell lung cancer, and combination studies with doxorubicin aimed at cardioprotection and enhanced efficacy in solid tumours. Racura collaborates with major research institutions worldwide and is exploring partnerships, licensing, or M&A to accelerate global access to RC220.
Average Trading Volume: 178,033
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.